Evidence map›Paper›PMID 36320665›Full record

ArticleJournal of hepatocellular carcinoma2022

Thrombotic Thrombocytopenic Purpura After Radiofrequency Ablation of Hepatocellular Carcinoma: A Case Report.

Renbiao Chen, Yonglei Zhao, Pierre Umba Mabombo, Hongjie Hu, Xiaoxuan Zhou

Abstract readCase Reports
In one paragraph

Article in Journal of hepatocellular carcinoma, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Renbiao ChenDepartment of Radiology, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, People's Republic of China.
Yonglei ZhaoDepartment of Radiology, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, People's Republic of China.
Pierre Umba MabomboDepartment of Radiology, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, People's Republic of China.
Hongjie HuDepartment of Radiology, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, People's Republic of China.
Xiaoxuan ZhouDepartment of Radiology, Sir Run-Run Shaw Hospital, Zhejiang University, Hangzhou, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiofrequency ablation (RFA) has become one of the commonly used treatment methods for hepatocellular carcinoma (HCC). It is widely available in the clinic and presents the advantages of short recovery time and a less invasive approach. Only a few complications, such as hemorrhage, ascites, and duct injury, have been reported after RFA for HCC. Herein, we report for the first time the case of a patient diagnosed with recurrent HCC in whom thrombotic thrombocytopenic purpura (TTP) was diagnosed as a complication of the RFA procedure. A 64-year-old male patient with a 2-year history of resected-stage V HCC, in whom later recurrence occurred, underwent RFA for HCC. This patient had a rapid drop in platelets and some petechiae on the wrists after RFA. Combining the clinical and laboratory tests, the diagnosis of TTP was reached. We immediately used plasmapheresis combined with drug therapy, which successfully treated the clinical condition of TTP, with no evidence of recurrence or other complications 1 year after initial treatment. TTP is a rare complication of RFA procedures. Prompt diagnosis and aggressive treatment measures are critical. Through this case report, we hope to raise awareness of the complications of RFA.

Indexed as

complicationhepatocellular carcinomaplasma exchangeradiofrequency ablationthrombotic thrombocytopenic purpura

Identifiers

PMID36320665
PMCPMC9618236

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.